Rare cancers are defined as those with an incidence of fewer than 6 per 100,000 people per year. Rare cancers account for 24% of all cancer diagnosis.
The prognosis of patients with a rare cancer is worse than that of patients with a non-rare cancer. Between 1995-1999 and 2015-2019, 5-year survival rates for rare cancers increased to a lesser extent (from 46.2% to 52.6%, i.e., 6.4%) than for common cancers (56.9% to 70.1%, i.e., 13.2%)
The mission of our research group is to improve prognosis of rare cancer patients by doing research. Examples of cancers in which our group is especially interested are:
We have a link with several research programs and with our phase I unit, to offer patients with rare cancers innovative medications. Furthermore, we work closely together with rare cancers patient societies.
Welcome to Research
We aim to improve prognosis of rare cancer patients by doing research.
Programs that are connected to this research group.
NL
DE
